Welcome to our dedicated page for Algernon Health news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Health stock.
Algernon Health Inc. (AGNPF), formerly Algernon Pharmaceuticals Inc., generates news that reflects its transition from a purely clinical-stage pharmaceutical developer to a healthcare company focused on brain-specific PET neuroimaging clinics and neurological programs. Company announcements highlight its plans to build a network of specialized clinics in North America for the early-stage detection of Alzheimer’s disease and other brain disorders, as well as updates on its drug development and subsidiary activities.
Investors and observers following AGNPF news will see disclosures about neuroimaging initiatives, including equipment orders and financing agreements for U.S. FDA-cleared brain PET systems, partnerships with imaging technology providers, and franchise and licensing arrangements obtained through the acquisition of NoBrainer Imaging Centers, Inc. These items outline how Algernon intends to deploy dedicated clinics and expand access to brain PET imaging in selected Canadian and U.S. markets.
News releases also cover Algernon’s ongoing pharmaceutical and neuroscience programs. This includes updates from Algernon NeuroScience, the company’s private subsidiary advancing a proprietary DMT program for stroke and traumatic brain injury, as well as intellectual property milestones for its chronic kidney disease candidate NP-251 (Repirinast). Additional coverage may address capital markets activity such as private placements, preferred share structures, and regulatory steps related to planned financings.
For readers tracking AGNPF, the news stream provides context on how Algernon is combining diagnostic imaging, clinic development, and drug research. Regularly reviewing these updates can help users understand changes in the company’s strategic focus, progress on clinic rollouts, developments in its neurological pipeline, and the evolution of its capital structure.
Algernon Pharmaceuticals has successfully completed its non-brokered private placement, issuing 11,260,040 units at CDN $0.25, raising gross proceeds of CDN $2,815,010. Each unit consists of one Class A common share and a warrant. The warrants allow for the purchase of additional shares at CDN $0.40 until March 5, 2023, with terms for accelerated expiry. The company paid CDN $161,400 in commissions and issued 645,600 finder’s warrants. Proceeds will be utilized for general corporate purposes.
Algernon Pharmaceuticals has announced a discussion on their DMT Stroke Clinical Research Program featuring CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt. The BioPub webcast is scheduled for March 3, 2021, at 1:00 PM EST, inviting stakeholders to engage in the conversation about the company's innovative approach to drug repurposing. Algernon focuses on exploring safe, approved drugs for new therapeutic applications, aiming to expedite new human trials and regulatory approvals.
Algernon Pharmaceuticals has announced a non-brokered private placement of 10,800,000 units, raising CAD $2,700,000. Each unit includes a common share priced at $0.25 and a share purchase warrant exercisable at $0.40 for 24 months. The warrants may expire early if the shares trade at or above CAD $0.80 for ten consecutive days. The proceeds will be allocated for general corporate purposes. Algernon focuses on drug repurposing for new disease applications, developing formulations, and seeking regulatory approvals.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) has awarded Hammersmith Medicines Research Ltd a contract for its Phase 1 stroke study of AP-188 (DMT). This study aims to assess the safety, tolerability, and pharmacokinetics of DMT dosages in healthy participants. Algernon plans to be the first globally to explore prolonged intravenous DMT infusion for stroke treatment. The study is set to inform future Phase 2 trials in stroke patients and is expected to start following the acquisition of cGMP drug product from Dalton Pharma.
Algernon Pharmaceuticals has appointed Dr. Christopher Bryan as Vice President of Research & Operations and Dr. Ahmad Khalil as Chief Medical Officer. Dr. Bryan, a PhD graduate from the University of Toronto, brings extensive experience in drug synthesis and clinical trial management. Dr. Khalil has over 20 years in biopharma, overseeing multiple clinical trials. The company announced that Dr. Mark Williams will step down as Chief Science Officer to lead a new venture. Algernon focuses on repurposing approved drugs for new applications.
On February 25, 2021, Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced that CEO Christopher J. Moreau and Dr. David Nutt will discuss the Company's New DMT Stroke Clinical Research Program at the Psychedelic Capital Virtual Investment Conference. This presentation will take place at 4:45 PM EST and is open for free access to shareholders, investors, and the public. Interested parties can find further information and access a free ticket through the provided link. Algernon is focused on drug repurposing and investigating safe, approved drugs for new medical applications.
Algernon Pharmaceuticals Inc. (CSE: AGN) has awarded a contract to Dalton Pharma Services for the manufacturing of the active pharmaceutical ingredient and finished product of AP-188 (DMT). This collaboration aims to facilitate the synthesis of DMT as Algernon prepares to file for a pre-IND meeting with the U.S. FDA and advance its Phase 1 and 2 clinical studies. The company is focused on leveraging positive pre-clinical data indicating DMT's potential in stroke treatment, with ongoing investigations into its effects on neuroplasticity.
On February 17, 2021, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) updated on its Phase 2b/3 study of Ifenprodil for COVID-19. A fire at a Romanian hospital site delayed the site audit, but the company has completed the source data audit for all patients. The database will be locked for analysis on March 5, and results will be shared soon after. Notably, many patients received imaging scans, aiding the exploration of Ifenprodil's potential in reducing post-COVID lung scarring, although the data will be reviewed separately to avoid further delays.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced plans to review its Phase 2b/3 study protocol for Ifenprodil in treating COVID-19, considering adding lung scarring as an endpoint based on new data from a significant patient population. Although lung scarring was not previously recognized as a major issue, recent studies indicate that 60% of post-COVID-19 patients exhibit lung damage. CEO Christopher J. Moreau emphasized that confirming Ifenprodil's effectiveness in this area could represent a significant advancement in patient care.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced a partnership with Charles River Laboratories to conduct preclinical studies on AP-188 (DMT) for its stroke research program. The study aims to explore DMT's neurogenic potential. The company intends to initiate human trials in 2021, focusing on sub-hallucinogenic doses to avoid adverse psychedelic effects in stroke patients. Previous studies indicated DMT's efficacy in reducing brain injury and promoting recovery. Algernon aims to be the first to investigate DMT for stroke treatment in humans.